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Innovations
Surface Logix
Mini Disease Models for Maximum Impact
who was a graduate student in the tages over other microfabrication
technologies. It is fast and flexibleWhitesides lab in the early nineties.
and easily interfaced with the labo-The basic principle behind the
Surface Logix is on a fast track to
revolutionizing the arts of pharma-
cological screening and cell biology.
Scientists using traditional cell- ratory. The silicon and glass formatsmethod starts with designing a mold
based protocols continually grapple commonly used to make biochipsusing CAD software to include spec-
with the problem that data gener- are expensive and are not easily ac-ified topographical and geometrical
ated from such assays can be diffi- commodated by a typical pharma-features required for a particular ex-
cult to interpret and unreliable. ceutical laboratory’s equipment.periment. This mold is then gener-
“From the pharmaceutical stand- Furthermore, the time needed forated from a wafer of glass or silicon
point, what is really a black box is the fabrication of biochips is tooby a mask aligner and photolithogra-
[how to look] at cells in an in vitro long for research that needs rapidphy, which burns the microfeatures
environment and get comfortable data turnaround. Another significantinto the surface. A layer of polymer
with the information that comes from benefit to using soft lithography isis then placed into the mold to create
assays or experiments so that you that silicon or glass is not always thean irreversibly bonded 3D surface
can really count on the data,” com- best material to mimic a biological
ments Carmichael Roberts, Presi- condition. This is emphasized by
“Cells are really smart indent of Surface Logix. To address Roberts, who feels that it is unrealis-
tic to consider cells cultured by stan-this pervasive issue, Surface Logix terms of recognizing their
is developing tools to conduct cell- dard protocol as representative ofmicroenvironment. We
based assays that are well-defined, “normal” cells. “Cells are really
saw a huge opportunity tostandardized, and controllable. This smart in terms of recognizing their
microenvironment,” he explains.50 person, Brighton, Massachu- take soft lithography (that
setts-based company is engaged in “We saw a huge opportunity to takeallows you to work downbuilding ex vivo models of human soft lithography (that allows you to
to the micro to nanodisease containing cells that accu- work down to the micro to nano
scale) and tune that microenviron-rately and robustly mimic cellular en- scale) and tune that mi-
vironments and tissues from healthy ment in a way that the cells actuallycroenvironment in a wayand diseased humans. Building become much more comfortable in
that the cells actually be-these disease models is a tremen- that in vitro environment. We can
look at the typical phenotypic re-dous challenge, but Surface Logix come much more com-
has tackled the problem head-on by sponses of cells and show that theyfortable in that in vitro en-harnessing the diverse technologies are behaving similar to the way that
vironment.”of soft lithography, microfabrication, they would in their natural envi-
ronment.”and customized surface chemistry. –Carmichael Roberts,
Additionally, detailed physiological This, however, is just the beginning.President, Surface Logixprofiles of different kinds of cells are Creating microworlds that are repre-
being produced by the research sentative of diseased or healthy
team to better understand what cells and tissues that can be used
ready for further chemical manipula-makes each individual cell type as human disease models is much
tion. Kim saw great commercial po-“tick.” more complex. Although it is a lofty
tential in the technology that he hadSoft lithography, which is a criti- goal, it seems to be well within the
created and consequently was thecal element of the pioneering Sur- grasp of the company. “Let’s say we
nucleating factor for the enterprise,face Logix technology, was initially look at inflammation,” explains Greg
which was cofounded by Robertsconceived by George Whitesides Kirk, Vice President of Technology,
and Whitesides in 1999. The initial(Harvard University). Whitesides en- “we can break down any number of
goal of Surface Logix was to indus-visioned systems where elastomers relevant cellular events that are of
trialize or commercialize a researchand polymers could be used as a interest to companies doing inflam-
tool or application centered aroundbackbone or template for patterning mation research. If you look at those
soft lithography that would be of rel-a wide range of kind of chemistries events and you map out what the
evance to the drug discovery pro-to reveal uncharacterized aspects of cells are actually doing, it is not triv-
cess; an idea that ultimately led toprotein biochemistry and cell biol- ial to duplicate that in the microenvi-
the concept of the development ofogy. This initial ideal blossomed into ronment.” Paul Sweetnam, Chief
complete ex vivo disease modelsa simple and elegant method due to Scientific Officer, continues, “First,
(Figure 1).the efforts of Enoch Kim, the princi- cells in the body don’t exist on glass
or plastic, they exist in the extracel-pal coinventor of soft lithography, This technique has distinct advan-
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cell actually does.” For example, in
the case of inflammation, endothe-
lial cells provide the vascular lining
through which the white blood cells
travel, and these cells can be either
cuboidal or elongated in appear-
ance. Cuboidal endothelial cells are
important for modeling the pathol-
ogy of atherosclerosis, but the long,
polarized endothelial cells play a
role in inflammation.
A major focus of Surface Logix’s en-
ergies and talents is in inflammation;
the second key area is ADMET (ab-
sorption, distribution, metabolism,
excretion, and toxicity) or pharma-
cokinetics: looking at how drugs act
in the body. Developing human-
based models of these systems that
will expand on traditional experi-
mental results and studies in animal
models is the cornerstone of the
Surface Logix scientific and busi-
ness plans. “As the number of tar-
gets and the chemistries improve, itFigure 1. Model of an Ex Vivo Biosystem
is becoming clear that animals don’tPrimary leukocytes can be activated under shear flow on a bed of endothelial cells. Motion
often reflect human physiology andand morphological changes can be quantitatively measured in these microenvironments.
Media flow is controlled in the model microscale capillary bed (compare the size of the dime that compounds made by the indus-
in [A] relative to the size of the capillary bed in the inset), and the surfaces are engineered try often don’t interact with animal
and patterned with immobilized biomolecules to support endothelial cell growth. The capillary receptors or enzymes,” states
bed is magnified in (D), which shows a fluorescent dye flowing through the engineered Sweetnam. Furthermore, he empha-
channels. The combination of flow and surface biochemistry causes the endothelial cells to
sizes that it is essential for research-align, elongate, and differentiate (E). A different set of surface chemistries cause primary
ers to understand that they could beleukocytes to activate and adhere to the synthetic capillary walls (B), or their adhesion can
be inhibited entirely (C). Chemokine gradients are also established that cause leukocytes to working with the wrong cells in the
migrate and change shape (F). first place: “The industry typically
works with continuous cell lines, and
since when is a tumor or immortal
lular matrix (ECM), so in our devices at the University of Chicago which cell line ever normal? You are testing
we have to mimic the ECM. We do provides links that bind peptides, noncancer diseases against tumor
this using a blend of synthetic poly- carbohydrates, or proteins in a pre- cells and that’s inappropriate.” Sur-
mers, hydrogels, and biomaterials. determined orientation to hook cells face Logix made a logical decision
Second, we have “stealth surface in specific immobilization schemes. to move away from cell lines and
technology”—we have to hide tradi- Using the Mrksich technology as a genetically engineered cells and use
tional surfaces because we don’t starting point, the company has the most appropriate cells for their
want cells interacting with glass or vastly expanded its biosurface biosystems, which are primary cells
plastic—those [surfaces] have to be chemistry platform to more effec- isolated directly from patients. The
invisible—and each protein in each tively design microenvironments major limitation with primary cells is
cell has a profile of what it considers that mimic the ECM. the number of cells that one can ac-
to be inert. Then we have to dial in Geometry and space also play a quire. However, this problem is
chemistries to make [the cells] com- huge role in cell behavior. “If you greatly aided by the innate beauty
fortable.” There are two primary ar- squeeze a cell into a very small of their miniaturized, microscale
eas of surface chemistry employed space, some cells will want to die in systems, since fewer cells are
by Surface Logix to create an opti- that space, some will want to divide, needed for each assay. Therefore,
mal microenvironment for the cells. and some will just be happy,” says more assays can be conducted us-
The first is surface engineering, Sweetnam. “Each cell has a per- ing the cells from each individual pa-
where the glass or polymer of the sonal space that it likes, and what tient. Surface Logix has also estab-
3D microenvironment is coated with we do is we define that personal lished a growing pool of over 100
single molecular layers. These mole- space.” Interestingly, physical donors from whom they regularly
cules are designed to meet the cells’ space can directly influence the harvest cells of interest for their in-
physical “needs,” or they can simply function of a cell, as Sweetnam elab- flammation program. “We are in the
be inert. The second area was devel- orates, “by changing their geometry, process of characterizing that donor
oped based on a technology that the we can change how the cell re- pool and putting it into batches. All
people are different, and we are in-company licensed from Milan Mrksich sponds, what it makes, and what the
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terested in things such as age, race, discovery and collaborating with
pharma to aid in their drug discoverysex; these are all key issues in what
cells do. In that regard, we are look- pipelines. Establishing alliances
with the intent of selling these toolsing at population dynamics as well
as the individual for every disease is a secondary goal. One possible
pitfall for Surface Logix lies in thestate,” explains Sweetnam. “What
we are doing now is looking at an availability of primary cells if the
company wants or needs to moveindividual patient and running a
breadth of assays. More information into other disease areas (like neuro-
biology or particular cancers) wheregives you a better chance of making
a better decision on what com- the cell source is limited—sources
such as tumor biopsies. However,pounds to bring forward and for
what disease. Inflammation actually they plan to play it safe for the imme-
diate future by sticking to inflamma-has a broad disease spectrum, so if
you run twenty assays, one can start tion as their field of interest, since
there is still a need for additionalto target clinical trials more effec-
tively.” By conducting several drug therapeutics to treat inflammatory
disease, and both blood and endo-assays using cells from donors with
well-defined disease profiles, the thelial cell collection are now rou-
tine practices.company will avoid the common pit-
falls of drug development that cur- The potential value and impact of
the Surface Logix ex vivo diseaserently face the pharmaceutical in-
dustry. Says Sweetnam, “If you look models is obviously great. These mi-
croscale systems are capable ofat failures in the clinic, there are an
increasing number of [drug] failures providing scientists with more phar-
macological information from moreat phase II. [Companies] get beauti-
ful drug-like molecules that are not assays in a shorter time frame: a
long-awaited breakthrough that willtoxic and show beautiful pK parame-
ters, but they have no efficacy be- surely mark a turning point in drug
development.cause they had the wrong assays to
predict what [disease] they should
Chemistry & Biology invites yourhave targeted in the clinic.”
comments on this topic. PleaseWithin the current glut of biotech
write to the editors at chembiol@companies, Surface Logix stands
cell.com.apart, occupying a niche filled with
little competition. Few other compa- Vicki Mountain is the Assistant Editor of
nies are capable of combining sur- Chemistry & Biology (vmountain@cell.com).
face chemistry, microfabrication,
cell biology, and 3D analysis in the
same way. Their true competition
lies within the biological disease re-
search that is going on within the
pharma companies themselves. Re-
gardless, Roberts is enthusiastic:
“We are biology driven, we use biol-
ogy expertise in-house, and we are
extremely fast and flexible around
the biology as it relates to disease.
In the short term, over the next cou-
ple of years, what we would really
like to do is to effectively apply our
ex vivo disease models to two or
three disease areas and develop
these ex vivo disease models to of-
fer a platform around each disease.
In the long term, we would like to be
considered an essential component
of the drug discovery process.” In
fact, the team’s primary goal is for
Surface Logix to become a premier
research and development house,
using the ex vivo disease models to
develop their own expertise in drug
